Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.

Trial Details

NCT ID
NCT04586478
Phase
PHASE2
Sponsor
Juventas Cell Therapy Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • single dose of CNCT19
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Patients who are willing to sign the informed consent form;
  • Aged 18-75 years, male or female;
  • At screening, subjects complying with the following diagnostic and treatment requirements:
  • Complying with CD19-positive NHL according to the WHO classification 2017, which are provided specifically as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →